Mary Cushman: Unprovoked VTE as a Marker of Increased Cardiovascular Mortality Risk
Mary Cushman, University Distinguished Professor and Vice Chair at the University of Vermont, shared Debora Kamin Mukaz‘s post on LinkedIn, adding:
“Alert! People with unprovoked VTE have double the risk of death than those without VTE.
Their leading cause of death is circulatory disease.
When you are seeing patients with VTE think big picture.
Start a statin if indicated.
Get bold pressure less than 130.
Talk about smoking cessation.”
Debora Kamin Mukaz, Assistant Professor of Medicine at Larner College of Medicine at the University of Vermont, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Journal of Thrombosis and Haemostasis:
“We published a new paper on long-term mortality and causes of death after venous thromboembolism (VTE) in Journal of Thrombosis and Haemostasis (JTH).
People with any VTE were approximately 3 times more likely to die over 5 years than those without VTE.
The 5-year mortality risk were approximately 6-fold for cancer-provoked VTE and 2-fold for unprovoked and other-provoked VTE.
Those with cancer-provoked VTE were most likely to die of cancer, but circulatory diseases were the main causes of death after all other types of VTE.
This suggests that enhanced cardiovascular prevention in patients with VTE might delay mortality.”
Title: Long-term mortality and causes of death after venous thromboembolism: findings from the Atherosclerosis Risk in Communities Cohort Study
Authors: Debora Kamin Mukaz, Aixin Li, Weihua Guan, Rui Cao, Lingfeng Huo, Weihong Tang, Pamela L Lutsey, Neil A Zakai, Aaron R Folsom, Mary Cushman

Other posts featuring Mary Cushman on Hemostasis Today.
-
Jul 20, 2026, 13:18Ekaterina Balaian: Submission Open for Special Issue on Hematologic Metabolism
-
Jul 20, 2026, 12:54Victor Emmanuel: Preventing Severe Maternal Complications Associated With Anemia
-
Jul 20, 2026, 12:33Ney Carter Borges: The Evolving Role of Aspirin in Coronary Artery Disease
-
Jul 20, 2026, 12:15Zain Khalpey: Why the Cause of Reduced Perfusion Matters
-
Jul 20, 2026, 11:53ISTH 2026 Showcases Landmark Research and Launches Women’s Health Hub
-
Jul 20, 2026, 10:40Omid Seidizadeh: Advancing Genomic Insights into Bleeding Disorders at ISTH 2026
-
Jul 20, 2026, 10:30Marc Blondon: What Are the Current Practices For VTE Prevention in Pregnancy Worldwide?
-
Jul 20, 2026, 10:11Zeyad Bady: Advancing Thrombosis Research on the International Stage at ISTH 2026
-
Jul 20, 2026, 09:41Emily Bury: From Emerging Evidence to Better Patient Care at ISTH 2026